The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.